Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:40 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
SaleCommon Stock | 3,000 | $148.63 | $445,879.50 |
DisclosureSEC source: 0001638643-26-000035 · wk-form4_1790973619.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 566,683 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3 · price: Sale prices for the transactions reported range from $148.23 to $149.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:40 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
SaleCommon Stock | 12,000 | $147.72 | $1,772,628.00 |
DisclosureSEC source: 0001638643-26-000035 · wk-form4_1790973619.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 569,683 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 · price: Sale prices for the transactions reported range from $147.21 to $148.205. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 22, 2026 Filed Sep 23, 2026 20:17 UTC |
Burkhart ErinSVP, Controllership
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001927648-26-000005 · wk-form4_1790194631.xml · derivative · entry 3 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,022 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 22, 2026 Filed Sep 23, 2026 20:17 UTC |
Burkhart ErinSVP, Controllership
|
Tax withholdingCommon Stock | 768 | $152.67 | $117,250.56 |
DisclosureSEC source: 0001927648-26-000005 · wk-form4_1790194631.xml · nonDerivative · entry 2 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,455 Read SEC document |
| September 22, 2026 Filed Sep 23, 2026 20:17 UTC |
Burkhart ErinSVP, Controllership
|
Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001927648-26-000005 · wk-form4_1790194631.xml · nonDerivative · entry 1 Burkhart Erin · CIK 0001927648 · SVP, Controllership 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:30 UTC |
Dickinson Andrew DChief Financial Officer
|
SaleCommon Stock | 3,000 | $145.29 | $435,870.00 |
DisclosureSEC source: 0001310204-26-000029 · wk-form4_1789590643.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,096 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:27 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
SaleCommon Stock | 600 | $145.29 | $87,174.00 |
DisclosureSEC source: 0001782135-26-000033 · wk-form4_1789590469.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,684 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:27 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
SaleCommon Stock | 800 | $144.46 | $115,565.52 |
DisclosureSEC source: 0001782135-26-000033 · wk-form4_1789590469.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,284 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3 · price: Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:27 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
SaleCommon Stock | 1,600 | $143.69 | $229,906.72 |
DisclosureSEC source: 0001782135-26-000033 · wk-form4_1789590469.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,084 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 · price: Sale prices for the transactions reported range from $143.16 to $144.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:30 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001310204-26-000027 · wk-form4_1789165843.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,054 Underlying: Common Stock · 2,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:30 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,347 | $144.81 | $195,059.07 |
DisclosureSEC source: 0001310204-26-000027 · wk-form4_1789165843.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,096 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:30 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001310204-26-000027 · wk-form4_1789165843.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:29 UTC |
Berger DietmarChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000011 · wk-form4_1789165789.xml · derivative · entry 3 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,395 Underlying: Common Stock · 533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:29 UTC |
Berger DietmarChief Medical Officer
|
Tax withholdingCommon Stock | 263 | $144.81 | $38,085.03 |
DisclosureSEC source: 0001739515-26-000011 · wk-form4_1789165789.xml · nonDerivative · entry 2 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,522 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:29 UTC |
Berger DietmarChief Medical Officer
|
Exercise / conversionCommon Stock | 533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000011 · wk-form4_1789165789.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000031 · wk-form4_1789165734.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,054 Underlying: Common Stock · 2,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
Tax withholdingCommon Stock | 1,347 | $144.81 | $195,059.07 |
DisclosureSEC source: 0001782135-26-000031 · wk-form4_1789165734.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,684 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
Exercise / conversionCommon Stock | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000031 · wk-form4_1789165734.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC |
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
|
Exercise / conversionRestricted Stock Unit · Derivative | 590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000013 · wk-form4_1789165685.xml · derivative · entry 3 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,405 Underlying: Common Stock · 590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC |
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
|
Tax withholdingCommon Stock | 285 | $144.81 | $41,270.85 |
DisclosureSEC source: 0002110603-26-000013 · wk-form4_1789165685.xml · nonDerivative · entry 2 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,759 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC |
Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
|
Exercise / conversionCommon Stock | 590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002110603-26-000013 · wk-form4_1789165685.xml · nonDerivative · entry 1 Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:27 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000033 · wk-form4_1789165629.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 8,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:27 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 4,230 | $144.81 | $612,546.30 |
DisclosureSEC source: 0001638643-26-000033 · wk-form4_1789165629.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,683 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:27 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 8,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001638643-26-000033 · wk-form4_1789165629.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:12 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
SaleCommon Stock | 5,408 | $149.38 | $807,856.23 |
DisclosureSEC source: 0001638643-26-000031 · wk-form4_1788379963.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,133 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F4 · price: Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:12 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
SaleCommon Stock | 7,992 | $148.36 | $1,185,721.89 |
DisclosureSEC source: 0001638643-26-000031 · wk-form4_1788379963.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 582,541 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F3 · price: Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:12 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
SaleCommon Stock | 1,600 | $147.51 | $236,013.92 |
DisclosureSEC source: 0001638643-26-000031 · wk-form4_1788379963.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 590,533 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 · price: Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,282 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · derivative · entry 8 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,569 Underlying: Common Stock · 10,282 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $60.67 | $0.00 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · derivative · entry 7 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,718 shares Expires 2030-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F6 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
SaleCommon Stock | 6,880 | $148.82 | $1,023,900.18 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 6 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,894 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F5 · price: Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
SaleCommon Stock | 3,402 | $148.24 | $504,296.49 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 5 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,774 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F4 · price: Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
Exercise / conversionCommon Stock | 10,282 | $61.35 | $630,800.70 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 4 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
SaleCommon Stock | 4,600 | $148.82 | $684,590.40 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 3 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,894 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F3 · price: Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
SaleCommon Stock | 3,118 | $148.31 | $462,432.45 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 2 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,494 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 · price: Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 22:44 UTC |
WELTERS ANTHONYDirector
|
Exercise / conversionCommon Stock | 7,718 | $60.67 | $468,251.06 |
DisclosureSEC source: 0001213307-26-000005 · wk-form4_1787870685.xml · nonDerivative · entry 1 WELTERS ANTHONY · CIK 0001213307 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 335 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · derivative · entry 12 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,395 Underlying: Common Stock · 335 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F6 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · derivative · entry 11 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,665 shares Expires 2031-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
SaleCommon Stock | 335 | $146.26 | $48,997.10 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 10 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionCommon Stock | 335 | $61.35 | $20,552.25 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 9 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
SaleCommon Stock | 26 | $146.36 | $3,805.36 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 8 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionCommon Stock | 26 | $67.45 | $1,753.70 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 7 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
SaleCommon Stock | 1,658 | $145.73 | $241,618.02 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 6 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F4 · price: Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionCommon Stock | 1,658 | $67.45 | $111,832.10 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 5 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
SaleCommon Stock | 1,816 | $144.92 | $263,183.44 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 4 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F3 · price: Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionCommon Stock | 1,816 | $67.45 | $122,489.20 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 3 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
SaleCommon Stock | 1,165 | $143.75 | $167,473.76 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 2 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. F2 · price: Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 23:22 UTC |
Bluestone JeffreyDirector
|
Exercise / conversionCommon Stock | 1,165 | $67.45 | $78,579.25 |
DisclosureSEC source: 0001771814-26-000005 · wk-form4_1787354535.xml · nonDerivative · entry 1 Bluestone Jeffrey · CIK 0001771814 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 23:06 UTC |
Dickinson Andrew DChief Financial Officer
|
SaleCommon Stock | 3,000 | $138.36 | $415,080.00 |
DisclosureSEC source: 0001310204-26-000024 · wk-form4_1787094366.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,646 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,890 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · derivative · entry 6 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,960 Underlying: Common Stock · 1,890 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC |
Mercier JohannaChief Comm & Corp Aff Officer
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 23,110 | $0.00 Strike: $66.64 | $0.00 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · derivative · entry 5 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,110 shares Expires 2029-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.